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with the bone marrow milieu, in which cytokine signals for growth and survival, such as IL-6 and VEGF, are received. The adhesion between malignant plasma cells and the marrow stromal cells themselves have also been shown to be important in the continuing survival of MM. 7 The IMiDs target many of these essential molecular pathways and are powerful new agents in clinical practice.
Clinical Trials of Immunomodulatory Drugs in

Relapsed or Refractory Multiple Myeloma
Thalidomide was first reported in 1999 to show clinical activity as monotherapy for MM. 8 Eighty that the combination of low-dose thalidomide (100mg daily) plus dexamethasone was an even more potent salvage therapy for relapsed/refractory MM, with a total 41% response rate and an additional 25% of patients maintaining stable disease. 9 The side effect of neuropathy was significant in 17% of the patients, prompting either dose reduction or discontinuation of therapy. A phase II trial conducted at our institution with the combination of clarithromycin (Biaxin ® ), low-dose thalidomide, and dexamethasone (BLT-D) in patients with previously treated MM or Waldenstrom's macroglobulinemia (or newly diagnosed patients unable to tolerate standard initial myelosuppressive therapy)
showed a high rate of response of 93% in the evaluable patients, including 13% complete remissions, 40% near-complete responses, 13% major responses, and 27% partial responses. 10 However, neurotoxocity was limiting as 18% of the patients developed grade 3 or higher neuropathy from BLT-D treatment.
Next, lenalidomide was tested in clinical trials with the hope that the side effect profile would be more favorable while maintaining the efficacy of thalidomide. Initial phase I studies of lenalidomide in patients with relapsed or refractory MM found that the maximal tolerated dose was 25mg daily, limited by myelosuppression. 11 A reduction of at least 25% in the M-spike (defined as minor response or better) was seen in 71% of the study participants. Moreover, 11 of 16 patients who had a history of prior thalidomide use responded to thalidomide. From this study, it appeared that lenalidomide could be used as a powerful agent in MM, had tolerable side effects, and was not cross-resistant to thalidomide.
A large multicenter phase II trial published in 2006 evaluated lenalidomide monotherapy in 102 patients with relapsed or refractory multiple myeloma. 12 Patients were initially randomized to one of two dosing schedules of lenalidomide: 15mg twice daily or 30mg once daily for 21 days of a 28-day cycle. Later interim analysis showed increased grade 3/4 myelosuppression in the twice-daily arm (41 versus 13%), and the subsequently enrolled patients were eventually assigned to the oncedaily group. The study was designed so that if a patient did not respond after two cycles of lenalidomide monotherapy, dexamethasone was added at a dose of 40mg daily for four days every two weeks.
Lenalidomide monotherapy was found to induce a minor response or better in 25% of patients. The standard practice of care for newly diagnosed symptomatic multiple myeloma is induction therapy to reduce the disease burden followed by high-dose chemotherapy with stem cell rescue. increase in the required number of days of apheresis. The duration of prior lenalidomide therapy and patient age were also both significant factors for the number of stem cells that were collected. Our group has corroborated these results and has found that that combination cyclophosphamide/G-CSF as a mobilization regimen effectively abrogates the negative impact of lenalidomide therapy, regardless of the length of prior treatment. The same investigator group that developed MPT next tested the combination of melphalan plus prednisone and low-dose lenalidomide (5-10mg daily for 21 days of a 28-day cycle) (RMP) in newly diagnosed elderly MM patients. 25 Eighty-one percent had an objective response rate to RMP, with a 24% complete response rate. The major toxicities were hematological and manageable and aspirin provided effective thrombosis prophylaxis, showing that similar rates of response with lower rates of toxicity could be achieved when using RMP versus MPT.
Randomized trials evaluating the efficacy of lenalidomide and dexamethasone at both low dose and high dose versus dexamethasone alone for newly diagnosed MM are currently under way to confirm the activity of this drug in the front-line setting.
The Myelodysplastic Syndromes
MDS are malignancies of the hematopoietic progenitor cells in the bone marrow that result in ineffective blood cell production. Patients with MDS often suffer from fatigue, bleeding, or increased susceptibility to infections due to underlying combinations of anemia, thrombocytopenia, and/or leucopenia. MDS is a clinically heterogeneous disease and is subclassified by the World Health Organization (WHO) on the basis of
bone marrow histological criteria as well as genetic markers, with a range of disease types from the slightly altered bone marrow findings (e.g. refractory anemia) to incipient acute leukemia (e.g. refractory anemia with excess blasts, type 2). 26 MDS have a high risk of progressing from a smoldering disease to acute leukemia, which loosely follows the WHO classification. This risk can be estimated using the International Prognostic Scoring System (IPSS), which takes into account variables to determine the probability of progression to acute leukemia, such as the percentage of bone marrow blasts, the presence of karyotype abnormalities, and the number of concurrent cytopenias present. 27 The most common karyotype abnormality seen in MDS is chromosome 5q31 interstitial deletion, which can be either isolated or associated with more complex karyotypes. MDS with isolated del(5q) has its own WHO classification. This is considered a more indolent MDS, characterized by hypoplastic anemia, dysplastic megakaryocytes, and a generally more favorable prognosis and lower IPSS scores than MDS with other cytogenetic abnormalities.
Thus far, the underlying pathophysiological abnormality in MDS has not been found, but there appear to be a number of factors involved. These include the increased replication of bone marrow stem cells with both disordered maturation and an increased rate of apoptosis, altered bone marrow stromal cell signaling activity characterized by overproduction of inflammatory and neovascular cytokines such as TNFα, IL-6, and VEGF, and a blunted response of bone marrow cells to physiological stimuli such as erythropoietin. There is also evidence that suggests an aberrant immune response is the cause of MDS in a subset of younger patients, as there have been responses to antithymocyte globulin therapy in this particular group.
Clinical Trials of Immunomodulatory Drugs in
Myelodysplastic Syndromes
The pro-inflammatory cytokine milieu, i.e. enhanced neo-angiogenesis and disordered immune response that characterize MDS, were postulated to be potential targets for immunomodulatory drugs.
Thalidomide was the first IMiD used for the treatment of MDS and
showed activity in about 30-50% of patients who took the drug for 12-16 weeks. 28, 29 Patients who responded tended to have a lower IPSS score and were manifested by a decrease in transfusion dependence, as well as in the percentage of blasts in the bone marrow. There was no association with any particular karyotype abnormality with the degree of response. The data appeared to be promising; however, virtually all study participants experienced side effects with the thalidomide therapy, which had to be given in the relatively large dose of 400mg daily. In the end, many patients, especially with higher-grade MDS by WHO classification, dropped out of the clinical trials due to excessive fatigue, constipation, and peripheral neuropathy.
Lenalidomide was the next agent tested for use in MDS, with the first reported trial in 2005. In this study, lenalidomide was prescribed to 53 MDS patients with low to intermediate IPSS scores with symptomatic or transfusion-dependent anemia. 30 Prior to enrollment, these patients were shown to be either refractory to erythropoietin (EPO) therapy or already had high circulating EPO levels and were thus not felt to benefit from further 
MDS associated with del(5q).
A second multicenter phase II trial, MDS-002, studied the effect of lenalidomide treatment in MDS, specifically excluding patients with interstitial deletions of chromosome 5q. 32 The study used the same entry criteria as the 
